CorPath PRECISE Clinical Study

The CorPath Percutaneous Robotically-Enhance Coronary Intervention Study (PRECISE) which received conditional IDE approval from the FDA is designed to evaluate the safety and effectiveness of the CorPath 200 System. The study will evaluate the clinical and technical performance of the CorPath 200 System in delivery and manipulation of PCI devices. The study is currently enrolling patients and is expected to enroll up to 175 patients.

The Principal Investigators for the trial are:

  • Dr. Joseph P. Carrozza Jr., Chief of Cardiovascular Medicine, Vice President of the Caritas Cardiovascular Network at St. Elizabeth's Medical Center, Boston, MA and Professor of Medicine, Tufts University School of Medicine
  • Dr.  Giora Weisz, Assistant Professor, Columbia University and director of research, Center for Interventional Vascular Therapy, New York-Presbyterian/Columbia University Medical Center, New York, NY 

Further information on the trial can be found at Clinicaltrials.gov